Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473460 | 1.00 | EPHX1 (0.50) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL1406894 | 0.86 | BTK (0.61) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL10343938 | 0.86 | BTK (0.61) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL3702152 | 0.86 | BTK (0.61) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL3702157 | 0.86 | BTK (0.61) | EPHX1BTKGAAKDM1AMAOB | |
| Methyl Alcohol SCHEMBL28082230 | 0.84 | BTK (0.59) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL20893335 | 0.82 | BTK (0.58) | EPHX1BTKGAAKDM1AMAOB | |
| Bicarbonate SCHEMBL187492 | 0.82 | BTK (0.62) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL20445292 | 0.82 | NPSR1 (0.60) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL12439739 | 0.81 | BTK (0.53) | EPHX1BTKGAAKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3093285-B1 | GADOLINIUM COMPLEX COMPRISING DO3A-TRANEXAMIC ACID CONJUGATE | KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) | 2020-07-08 | — | — | EP | disclosed |
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-10633366-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-04-28 | — | — | US | disclosed |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-03-26 | — | — | US | disclosed |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-08-22 | — | — | US | disclosed |
| US-20190161472-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-05-30 | — | — | US | disclosed |
| US-10245328-B2 | Gadolinium complex comprising DO3A-tranexamic acid conjugate | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-04-02 | — | — | US | disclosed |
| WO-2017211759-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211760-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-14 | — | — | WO | disclosed |
| EP-3019492-B1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | BOEHRINGER INGELHEIM INT (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-1775298-B1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161472-A1 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, LAS1L, MRPL19 | EPHX1 2997/4885BTK 2361/4885GAA 1144/4885 |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | EPHX1 3978/4885BTK 2968/4885GAA 969/4885 |
| US-10633366-B2 | Antibacterial compounds | MRPL21, LAS1L, MRPL19 | EPHX1 3312/4885BTK 1854/4885GAA 846/4885 |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | PDE7A, PDE7B, PDE3B | EPHX1 2147/4885BTK 1602/4885GAA 3005/4885 |
| US-10245328-B2 | Gadolinium complex comprising DO3A-tranexamic acid conjugate | F13A1, SERPINC1, F3 | EPHX1 3338/4885BTK 4806/4885GAA 1188/4885 |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | EPHX1 3978/4885BTK 2968/4885GAA 969/4885 |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | PDE7A, PDE7B, PDE3B | EPHX1 2147/4885BTK 1602/4885GAA 3005/4885 |
| US-10640488-B2 | Antibacterial compounds | MRPL21, CLPP, NRDC | EPHX1 3980/4885BTK 3372/4885GAA 596/4885 |
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | EPHX1 4028/4885BTK 297/4885GAA 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.